Axis Capital Holdings Ltd. (AXS)
NYSE NYSE Primary 
XFRA 
Why Axis Capital (AXS) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Axis Capital (AXS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Axis Capital Holdings (AXS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Axis Capital Holdings (AXS) Stock Outpacing Its Finance Peers This Year?
Here is how Axis Capital (AXS) and Mr Cooper (COOP) have performed compared to their sector so far this year.
AXS or TKOMY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Insurance - Property and Casualty sector have probably already heard of Axis Capital (AXS) and Tokio Marine Holdings Inc. (TKOMY). But which of these two stocks offers value investors a better bang for their buck right now?
5 Low Price-to-Book Value Stocks to Buy in December
The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, SEM, AXS, ZIM and PFE are some such stocks.
4 Best Value Stocks to Invest in This December for Strong Returns
Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, AXS, PFE & GM boast a low P/CF ratio.
Why Is Axis Capital (AXS) Up 19.9% Since Last Earnings Report?
Axis Capital (AXS) reported earnings 30 days ago. What's next for the stock?
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial, with current treatments having issues like tolerability and efficacy, which AXS-12 aims to address effectively. Financially, Axsome has a market cap of $4.83bn, strong revenue growth, but a net loss, indicating a cash runway of four to five quarters.
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
On Tuesday, Axsome Therapeutics Inc AXSM said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial.
AXIS Capital Rallies 65% YTD: Time to Buy the Stock for Solid Returns?
AXS continues to build on specialty insurance, reinsurance as well as the accident and health portfolio.
Axis Capital Holdings Limited (AXS) Hits Fresh High: Is There Still Room to Run?
Axis Capital (AXS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
